APA aipamena

Cheah, C. Y., Nastoupil, L. J., Neelapu, S. S., Forbes, S. G., Oki, Y., & Fowler, N. H. (2015). Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood.

Chicago Style aipamena

Cheah, Chan Yoon, Loretta J. Nastoupil, Sattva S. Neelapu, Sheryl G. Forbes, Yasuhiro Oki, and Nathan H. Fowler. "Lenalidomide, Idelalisib, and Rituximab Are Unacceptably Toxic in Patients With Relapsed/refractory Indolent Lymphoma." Blood 2015.

MLA aipamena

Cheah, Chan Yoon, et al. "Lenalidomide, Idelalisib, and Rituximab Are Unacceptably Toxic in Patients With Relapsed/refractory Indolent Lymphoma." Blood 2015.